» Articles » PMID: 27552105

Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography

Overview
Journal PLoS One
Date 2016 Aug 24
PMID 27552105
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The epidermal growth factor receptor (EGFR) is overexpressed in many cancers including lung, ovarian, breast, head and neck and brain. Mutation of this receptor has been shown to play a crucial role in the response of non-small cell lung carcinoma (NSCLC) to EGFR-targeted therapies. It is envisaged that imaging of EGFR using positron emission tomography (PET) could aid in selection of patients for treatment with novel inhibitors. We recognised multi-drug resistant phenotype as a threat to development of successful imaging agents. In this report, we describe discovery of a novel cyanoquinoline radiotracer that lacks ABC transporter activity.

Methods: Cellular retention of the prototype cyanoquinoline [18F](2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}-4-({[1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}amino)-but-2-enamide ([18F]FED6) and [18F](2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}-4-[({1-[(2R,5S)-3-fluoro-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)amino]but-2-enamide ([18F]FED20) were evaluated to establish potential for imaging specificity. The substrate specificity of a number of cyanoquinolines towards ABC transporters was investigated in cell lines proficient or deficient in ABCB1 or ABCG2.

Results: FED6 demonstrated substrate specificity for both ABCG2 and ABCB1, a property that was not observed for all cyanoquinolines tested, suggesting scope for designing novel probes. ABC transporter activity was confirmed by attenuating the activity of transporters with drug inhibitors or siRNA. We synthesized a more hydrophilic compound [18F]FED20 to overcome ABC transporter activity. FED20 lacked substrate specificity for both ABCB1 and ABCG2, and maintained a strong affinity for EGFR. Furthermore, FED20 showed higher inhibitory affinity for active mutant EGFR versus wild-type or resistant mutant EGFR; this property resulted in higher [18F]FED20 cellular retention in active mutant EGFR expressing NSCLC.

Conclusion: [18F]FED20 binds EGFR but is devoid of ABC transporter activity, thus, has potential for EGFR imaging.

Citing Articles

Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.

Radaram B, Pisaneschi F, Rao Y, Yang P, Piwnica-Worms D, Alauddin M Eur J Med Chem. 2019; 182:111571.

PMID: 31425908 PMC: 7193943. DOI: 10.1016/j.ejmech.2019.111571.


The Continuing Evolution of Molecular Functional Imaging in Clinical Oncology: The Road to Precision Medicine and Radiogenomics (Part I).

Vaidya T, Agrawal A, Mahajan S, Thakur M, Mahajan A Mol Diagn Ther. 2018; 23(1):1-26.

PMID: 30411216 DOI: 10.1007/s40291-018-0366-4.

References
1.
Cobo M, Isla D, Massuti B, Montes A, Miguel Sanchez J, Provencio M . Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007; 25(19):2747-54. DOI: 10.1200/JCO.2006.09.7915. View

2.
Chen Y, Huang W, Wei Y, Hsu S, Yuan P, Lin H . Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One. 2011; 6(6):e21428. PMC: 3121773. DOI: 10.1371/journal.pone.0021428. View

3.
de Bruin E, Cowell C, Warne P, Jiang M, Saunders R, Melnick M . Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 2014; 4(5):606-19. PMC: 4011693. DOI: 10.1158/2159-8290.CD-13-0741. View

4.
Didziapetris R, Japertas P, Avdeef A, Petrauskas A . Classification analysis of P-glycoprotein substrate specificity. J Drug Target. 2004; 11(7):391-406. DOI: 10.1080/10611860310001648248. View

5.
Shepard R, Cao J, Starling J, Dantzig A . Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer. 2002; 103(1):121-5. DOI: 10.1002/ijc.10792. View